We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Analytical Tool Could Replace Traditional Biopsies with Liquid Biopsies for Disease Diagnosis

By LabMedica International staff writers
Posted on 17 Jul 2024
Print article
Image: Through EV Fingerprinting, researchers fluorescently label EVs and detect them with flow cytometry (Photo courtesy of von Lersner et al., shared under a CC by 4.0 license)
Image: Through EV Fingerprinting, researchers fluorescently label EVs and detect them with flow cytometry (Photo courtesy of von Lersner et al., shared under a CC by 4.0 license)

Biopsies are important clinical tools used to diagnose various diseases or monitor tissues for abnormal growth or transplant rejection. Typically, this involves removing tissue samples from the body for closer examination, which can be invasive depending on the tissue required. Researchers have developed a new analytical method that could enable the use of "liquid biopsies" as an alternative to traditional biopsies for certain patients or diseases.

This new tool, developed by researchers from Vanderbilt University’s School of Medicine Basic Sciences (Nashville, TN, USA), is known as EV Fingerprinting, where EV stands for extracellular vesicles. EVs are membrane-bound particles filled with biologically active materials that play a crucial role in cell-cell communication in both health and disease. Although EVs have been studied since the 1980s, their origins and functions have not been fully defined. Research on EVs has intensified over the last two decades, revealing their involvement in processes such as endocrinology, immune responses, and even cancer progression across various species, including humans. The term EV encompasses vesicles of different sizes and cargoes, each likely specialized for different functions. Variations in the heterogeneity of EVs within an organism can indicate changes in its biological state—such as transitioning from a normal to a cancerous state—which can be used as a clinically informative biomarker.

The fingerprinting technique allows for the characterization of EVs with minimal sample preparation in a high-throughput manner, enabling better classification of the vesicle types present in the sample. The technique highlighted in a paper published in ACS Nano in April 2024 involves isolating EVs from other cellular materials in a sample, staining them with a fluorescent lipophilic dye that integrates into the EVs’ lipid bilayers, and processing them through a flow cytometer. This instrument directs a laser at the sample and gathers data on how the light is scattered or emitted. The data is then compiled into a "fingerprint" that facilitates quantitative analysis of different EV populations and assesses how these populations change due to experimental manipulations, molecular disturbances, or disease states. EV Fingerprinting marks a significant step forward in the characterization of EVs, offering insights into the composition of the lipid bilayers of the EVs in a sample and segregating them into distinct populations—something not achievable with previous bulk analysis methods. This innovative approach, which utilizes the composition of the lipid bilayers—a previously underexplored characteristic of EVs—could one day replace traditional biopsy methods with a simple blood draw, greatly benefiting patients requiring diagnostic testing.

“EV Fingerprinting is furthering the development of liquid biopsies in which the EVs can be used as biomarkers for diseases such as cancers or neurological disorders,” said Ariana von Lersner, a former graduate student and current postdoctoral scholar whose dissertation work culminated in the development of the EV Fingerprinting tool.

Related Links:
Vanderbilt University’s School of Medicine Basic Sciences

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TRAcP 5b Assay
TRAcP 5b (BoneTRAP) Assay
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.